Tectonic Therapeutic (TECX) CSO awarded options, RSUs and sells shares

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. Chief Scientific Officer Peter McNamara reported a mix of equity awards and share sales. On March 4, 2026, he received an option grant for 21,000 shares at $0.0000 per share, vesting in 48 equal monthly installments beginning April 4, 2026, subject to continued service.

He also acquired 23,000 shares of common stock in the form of restricted stock units, each representing one share, vesting in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, also subject to continued service. The filing shows open‑market sales of 1,649 shares at $22.06 on March 3, 2026 and 1,650 shares at $25.00 on March 4, 2026, pursuant to a Rule 10b5‑1 trading plan adopted on November 14, 2025. Following these transactions, he directly owned 58,832 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McNamara Peter

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		1,649	D	$22.06	37,482	D
Common Stock	03/04/2026		A		23,000(2)	A	$0	60,482	D
Common Stock	03/04/2026		S(1)		1,650	D	$25	58,832	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$27.41	03/04/2026		A		21,000		(3)	03/03/2036	Common Stock	21,000	$0	21,000	D

Explanation of Responses:

1. These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2025.

2. These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did TECX executive Peter McNamara report?

Peter McNamara reported equity awards and share sales. He received 21,000 stock options and 23,000 restricted stock units, and sold a total of 3,299 common shares in two open‑market transactions executed under a pre‑arranged Rule 10b5‑1 trading plan.

How many TECX shares did Peter McNamara sell and at what prices?

He sold 3,299 common shares in total. The sales were 1,649 shares at $22.06 on March 3, 2026 and 1,650 shares at $25.00 on March 4, 2026, executed as open‑market transactions under a Rule 10b5‑1 trading plan.

What stock option grant did TECX award to Peter McNamara?

He received an employee stock option covering 21,000 shares at an exercise price of $0.0000 per share. The option vests in 48 equal monthly installments starting April 4, 2026, conditioned on his continued service with Tectonic Therapeutic on each monthly vesting date.

What restricted stock unit (RSU) award did TECX grant Peter McNamara?

He was granted 23,000 shares represented by restricted stock units, each RSU equal to one common share. These RSUs vest in three equal annual installments on March 4, 2027, March 4, 2028, and March 4, 2029, subject to his continued service with the company.

Was Peter McNamara’s TECX stock sale part of a Rule 10b5-1 plan?

Yes. The filing states that the reported sales were made under a Rule 10b5‑1 trading plan adopted by Peter McNamara on November 14, 2025, providing a pre‑arranged schedule for selling shares independent of future material nonpublic information.

How many TECX shares did Peter McNamara own after these transactions?

After the reported transactions, Peter McNamara directly owned 58,832 shares of Tectonic Therapeutic common stock. This figure reflects his holdings following the combination of equity awards and open‑market sales disclosed for early March 2026 in the Form 4 filing.